Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019
January 14, 2020 at 09:03 pm
Share
Regenicin, Inc. announced earnings results for the full year ended September 30, 2019. For the full year, the company announced operating loss was USD 736,553 compared to USD 540,277 a year ago. Net loss was USD 758,456 compared to USD 559,058 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to Basic EPS - Continuing Operations of USD 0 a year ago.
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.